Avidity Biosciences, Inc. (NASDAQ:RNA – Get Rating)’s share price traded down 6.4% during trading on Tuesday . The stock traded as low as $11.67 and last traded at $11.69. 8,402 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 633,947 shares. The stock had previously closed at $12.49.
Wall Street Analysts Forecast Growth
RNA has been the subject of several recent analyst reports. Chardan Capital reduced their target price on Avidity Biosciences from $29.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, September 27th. Needham & Company LLC cut their price target on Avidity Biosciences from $50.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, September 27th. Credit Suisse Group raised their price target on Avidity Biosciences from $32.00 to $33.00 and gave the stock an “outperform” rating in a report on Wednesday, November 9th. Finally, Raymond James increased their price objective on Avidity Biosciences from $29.00 to $30.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, November 9th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Avidity Biosciences currently has an average rating of “Buy” and an average target price of $39.50.
Avidity Biosciences Stock Up 1.5 %
The stock has a 50-day simple moving average of $15.61 and a two-hundred day simple moving average of $16.30. The firm has a market cap of $661.14 million, a PE ratio of -3.71 and a beta of 0.81.
Institutional Investors Weigh In On Avidity Biosciences
About Avidity Biosciences
Avidity Biosciences, Inc, a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage.
- Get a free copy of the StockNews.com research report on Avidity Biosciences (RNA)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.